A current research led by the College of Oxford, referred to as the Com-COV3 research, has revealed promising findings from trials involving the Novavax vaccine, Nuvaxovid, and concerning the immune response and facet impact profile of “blended” two-dose COVID-19 vaccine schedules in adolescents aged 12 to 16 years.
The research administered both a full or a one-third (fractional) dose of the Pfizer-BioNTech COVID-19 vaccine, or a full dose of the Novavax vaccine, a minimum of eight weeks after the primary full dose of the Pfizer-BioNTech vaccine.
The researchers printed their findings within the Journal of Infection, reporting {that a} blended schedule combining a full dose of Pfizer-BioNTech adopted by a full dose of Novavax resulted in fewer breakthrough infections and better antibody and T-cell responses in comparison with the licensed two full dose (homologous) Pfizer-BioNTech schedule. This blended schedule demonstrated effectiveness towards each wild-type COVID-19 and the omicron variants (BA.1 and BA.2).
Alternatively, a full dose of Pfizer-BioNTech adopted by a fractional (one-third) dose of the identical vaccine produced decrease antibody concentrations to wild-type COVID-19 however generated comparable neutralizing antibodies as two full doses of Pfizer-BioNTech towards each omicron variants.
The research members who acquired the fractional dose of Pfizer-BioNTech as their second vaccine reported fewer and milder negative effects in comparison with the opposite teams. Notably, no vaccine-related security considerations had been raised among the many 148 members aged 12 to 16.
This groundbreaking analysis is the primary randomized managed trial to look at the immune response and facet impact profiles of ordinary and blended vaccine COVID-19 schedules in adolescents.
In a news release, Dr. Angela Minassian, chief investigator on the trial from the Oxford Vaccine Group, expressed her gratitude for the collaborative effort between U.Okay. websites and the participation of younger people. She emphasised that the blended and fractional vaccine schedules studied had been well-tolerated and generated strong immune responses in adolescents for a minimum of eight months. The improved efficiency of Novavax’s protein subunit vaccine following a dose of Pfizer-BioNTech’s mRNA vaccine is especially noteworthy, suggesting a possible broader safety when totally different vaccine platforms are mixed.
Dr. Eimear Kelly, co-author and Pediatric Analysis Fellow on the Oxford Vaccine Group, Division of Pediatrics, highlighted the spectacular efficiency of Novavax towards wild-type and omicron SARS-CoV-2 variants. The outcomes offered supportive proof for the usage of Novavax as a part of a blended COVID-19 vaccine schedule, which presents flexibility and enhances international vaccine provides.
In associated information, Novavax recently announced that its protein-based vaccine Nuvaxovid, also referred to as NVX-CoV2373, has been granted full advertising authorization by the European Fee for the prevention of COVID-19.
The vaccine is now licensed to be used as a major collection in people aged 12 and older and as a booster shot for adults aged 18 and older inside the European Union. The choice adopted the endorsement of Nuvaxovid by an professional panel on the European Medicines Company.
Revealed by Medicaldaily.com